foxo4-dri vs gdf-11

foxo4-dri vs gdf-11 The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI alleviates age-related testosterone secretion

Name: foxo4-dri vs gdf-11 The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI alleviates age-related testosterone secretion
Brand: hgidocs.co
SKU: 3344849737
Price: 23.30 USD
Availability: InStock
Rating: 4.504 (19 reviews)

FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice PMC GDF11 and aging biology controversies resolved and pending PMC Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging PMC Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine FOXO4 DRI FOXO4 p53 Interaction Blocker MedChemExpress

SKU: 3344849737 · From hgidocs.co

4.5

USD23.30 USD45.30

Pay in 4 interest-free payments of $5.83 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

The CS-coefficient for bridge strength was 0.517, suggesting moderate stability

It depends on temperature: the higher the temperature, the more soluble the compound will be in water

This can be conveniently estimated from the creatinine clearance, calculated from a single serum creatinine measurement and the predicted creatinine production rate

A.et al (2021)

Peptide therapy for skin rejuvenation addresses aging at that deeper level by giving cells the signaling molecules they need to behave like younger tissue